Atom | Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Funder: National Institutes of Health (NIH)

Funding Amounts: UG3 phase up to 1 year; UH3 phase up to 4 years; budgets reflect project needs with no set cap.

Summary: Supports neuroscience researchers in small molecule drug discovery and development for nervous system disorders, from hit optimization through IND-enabling studies and Phase I clinical trials, with awardees retaining intellectual property rights.

Key Information: Cooperative agreement mechanism with substantial NIH involvement; clinical trial optional; projects enter at Discovery or Development stage; strong emphasis on milestones and IP management.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Sign in to see full grant listing